FLT3 belonging Ⅲ receptor tyrosine kinase family (receptor tyrosine kinase Ⅲ Family, the RTK Ⅲ) . The members of this family also include c-KIT receptor, platelet-derived growth factor receptor and c-FMS receptor, etc. The genes of each member of this family have high homology. FLTS contains 5 extracellular ligand binding domains composed of immunoglobulin poplar structure, 1 transmembrane domain, 1 intracellular proximal membrane domain, 2 kinase domains separated by insertion domains, and a C- terminal- Structure domain [1] . FLT3 is expressed in liver, spleen, lymph, brain, placenta and other tissues , and plays an important role in the proliferation, differentiation and apoptosis of hematopoietic stem cells, pre- B cells, and dendritic cells. [2] In addition, studies have found that the onset of acute myeloid leukemia is often accompanied by abnormal activation of FLT3 [3] , so FLT3 may be used as a potential therapeutic target for acute myeloid leukemia . This product is FLT3-entrokinas- FCRecombinant protein ( FC tag can be removed by enterokinase), which can be used for monoclonal antibody screening or antibody function verification.

Product name: Recombinant human FLT3 protein

Species: Human origin

Gene sequence number: P36888

Tags: Human-Fc Tag

Tag site: N- terminal

Restriction site: enterokinase

Expression area: extracellular segment ( 27-543AA)

Host cell: CHO-S

Purity: ＞ 90%

Purification method: Protein A column

Preservation system: PBS+20% glycerol

Storage conditions: -80℃

Illustration: Lane M on the left is protein MW marker, Lane 1 is 10ug FLT3-Fc protein;

The image on the right shows the FACS detection of FLT3 protein binding to 293T overexpressing anti-FLT3-CAR.

Reference materials:

1. Genomic structure of human Flt3： implications for mutational analysis

2. Flt3-dependent transformation by inactivating c-Cbl mutations in AML

3.Flt3-ITD and tyrosine kinase domain mutants induce-distinct phenotypes in a murine bone marrow transplantation model